136 related articles for article (PubMed ID: 38306117)
1. Comparison of S100A8 and PRAME as biomarkers for distinguishing melanoma from melanocytic naevus: a case-control analysis.
Hai J; Meyer SN; Wong SL; Li Y; Simmons E; Miglioretti D; Fung MA; Kiuru M
Clin Exp Dermatol; 2024 May; 49(6):584-590. PubMed ID: 38306117
[TBL] [Abstract][Full Text] [Related]
2. PRAME Immunohistochemistry for Distinguishing Vulvar and Vaginal Melanoma From Benign Melanocytic Nevi.
Martin SD; Martin KC; Gilks CB; Crawford RI; Hoang LN
Int J Gynecol Pathol; 2024 Jul; 43(4):389-396. PubMed ID: 38085951
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
Lezcano C; Jungbluth AA; Busam KJ
Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic utility of PRAME and p16 in distinguishing nodal nevi from nodal metastatic melanoma.
See SHC; Finkelman BS; Yeldandi AV
Pathol Res Pract; 2020 Sep; 216(9):153105. PubMed ID: 32825968
[TBL] [Abstract][Full Text] [Related]
5. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF; Oh KS; Alexis J
J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics.
Rawson RV; Shteinman ER; Ansar S; Vergara IA; Thompson JF; Long GV; Scolyer RA; Wilmott JS
Pathology; 2022 Dec; 54(7):863-873. PubMed ID: 35987723
[TBL] [Abstract][Full Text] [Related]
7. The utility of PRAME staining in identifying malignant transformation of melanocytic nevi.
Lohman ME; Steen AJ; Grekin RC; North JP
J Cutan Pathol; 2021 Jul; 48(7):856-862. PubMed ID: 33433032
[TBL] [Abstract][Full Text] [Related]
8. [Application of immunohistochemical staining of PRAME in differential diagnosis between melanoma and melanocytic nevus].
Du J; Yu WJ; Guo RP; Su J
Zhonghua Bing Li Xue Za Zhi; 2022 Jul; 51(7):621-626. PubMed ID: 35785832
[No Abstract] [Full Text] [Related]
9. Diagnostic utility of PRAME in distinguishing proliferative nodules from melanoma in giant congenital melanocytic nevi.
Gill P; Prieto VG; Austin MT; Giubellino A; Torres-Cabala CA
J Cutan Pathol; 2021 Nov; 48(11):1410-1415. PubMed ID: 34164835
[TBL] [Abstract][Full Text] [Related]
10. The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors.
Alomari AK; Tharp AW; Umphress B; Kowal RP
J Cutan Pathol; 2021 Sep; 48(9):1115-1123. PubMed ID: 33660310
[TBL] [Abstract][Full Text] [Related]
11. PRAME expression by immunohistochemistry and reverse transcription quantitative PCR in conjunctival melanocytic lesions-a comprehensive clinicopathologic study of 202 cases and correlation of cytogenetics with PRAME expression in challenging conjunctival melanocytic lesions.
Mudhar HS; Milman T; Stevenson S; Watson M; Kim J; Magan T; Salvi SM; Harley U; Lally SE; Shields CL
Hum Pathol; 2023 Apr; 134():1-18. PubMed ID: 36804828
[TBL] [Abstract][Full Text] [Related]
12. Performance of preferentially expressed antigen in melanoma (PRAME) immunohistochemistry for metastatic melanoma in cytology specimens.
Saad M; Cantley R; Hao W; Wang Z; Thomas D; Pantanowitz L; Jin X
Diagn Cytopathol; 2024 Jul; 52(7):362-368. PubMed ID: 38558495
[TBL] [Abstract][Full Text] [Related]
13. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
Googe PB; Flanigan KL; Miedema JR
Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
[TBL] [Abstract][Full Text] [Related]
14. Analysis of PRAME immunocytochemistry in 109 acral malignant melanoma in situ.
Miao QJ; Zang J; Shao XB; Sun JF; Chen YP; Chen H
J Clin Pathol; 2024 May; 77(6):417-420. PubMed ID: 36882315
[TBL] [Abstract][Full Text] [Related]
15. PRAME Immunohistochemical Expression and TERT Promoter Mutational Analysis as Ancillary Diagnostic Tools for Differentiating Proliferative Nodules From Melanoma Arising in Congenital Nevi.
Boutko A; Hagstrom M; Lampley N; Roth A; Olivares S; Dhillon S; Fumero-Velázquez M; Benton S; Zhao J; Zhang B; Dittmann D; Asadbeigi S; Busam KJ; Gerami P
Am J Dermatopathol; 2023 Jul; 45(7):437-447. PubMed ID: 37338065
[TBL] [Abstract][Full Text] [Related]
16. Performance of PRAME immunohistochemistry compared with that of c-Kit, c-Myc, or cyclin D1 for the diagnosis of acral melanocytic tumors.
Jung JM; Lee MY; Won CH; Chang SE; Lee MW; Lee WJ
Pathol Int; 2023 Jan; 73(1):27-36. PubMed ID: 36468840
[TBL] [Abstract][Full Text] [Related]
17. PRAME immunohistochemistry is useful in the evaluation of conjunctival melanomas, nevi, and primary acquired melanosis.
LeBlanc RE; Miller DM; Zegans ME
J Cutan Pathol; 2021 Dec; 48(12):1442-1448. PubMed ID: 34089198
[TBL] [Abstract][Full Text] [Related]
18. Refining the application of PRAME-a useful marker in high CSD and acral melanoma subtypes.
Wakefield C; O'Keefe L; Heffron CCBB
Virchows Arch; 2023 Dec; 483(6):847-854. PubMed ID: 37723345
[TBL] [Abstract][Full Text] [Related]
19. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
20. FLI-1/Melan-A dual stain is an alternative to PRAME in differentiating metastatic melanoma from nodal nevus: A monocentric retrospective study.
Zengin HB; Yildiz B; Pukhalskaya T; Smoller BR
J Cutan Pathol; 2023 Mar; 50(3):247-258. PubMed ID: 36454046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
